Table 2. Sociodemographic variables associated with use of first-line therapy among participants with self-reported coronary heart disease.
| ASA | Beta blockers | ACEI | Statins | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
P-value |
|
|
P-value |
|
|
P-value |
|
|
P-value | |
| Age (mean, SD) | 59.3 (8.3) | 62.2 (7.6) | 0.0004 | 60.2 (8.4) | 61.4 (7.7) | 0.145 | 60.4 (8.4) | 61.8 (7.3) | 0.082 | 58.7 (8.5) | 62.3 (7.4) | < 0.0001 |
| Age stratum (%) | ||||||||||||
| 35-44 | 7 (3.8) | 0 (0.0) | 0.002 | 6 (3.2) | 1 (0.2) | 0.148 | 7 (2.7) | 0 (0.0) | 0.111 | 7 (4.3) | 0 (0.0) | < 0.0001 |
| 45-54 | 47 (25.5) | 39 (17.7) | 43 (22.8) | 43 (20.0) | 61 (23.2) | 25 (17.7) | 45 (27.6) | 41 (17.0) | ||||
| 55-64 | 78 (42.4) | 94 (42.7) | 80 (42.3) | 92 (42.8) | 106 (40.3) | 66 (46.8) | 71 (43.6) | 101 (41.9) | ||||
| 65-74 | 52 (28.3) | 87 (39.5) | 60 (31.7) | 79 (19.6) | 89 (33.8) | 50 (35.5) | 40 (24.5) | 99 (41.1) | ||||
| Sex (%) | ||||||||||||
| Male | 96 (52.2) | 160 (72.7) | < 0.0001 | 109 (57.7) | 147 (68.4) | 0.026 | 156 (59.3) | 100 (70.9) | 0.021 | 78 (47.9) | 178 (73.9) | < 0.0001 |
| Female | 88 (47.8) | 60 (27.3) | 80 (42.3) | 68 (31.6) | 107 (40.7) | 41 (29.1) | 85 (52.1) | 63 (26.1) | ||||
| Race (%) | ||||||||||||
| White | 79 (43.4) | 133 (62.1) | 0.0003 | 88 (46.8) | 124 (59.6) | 0.076 | 133 (52.0) | 79 (56.4) | 0.706 | 64 (39.8) | 148 (63.0) | < 0.0001 |
| Mixed | 48 (26.4) | 50 (23.4) | 50 (26.6) | 48 (23.1) | 68 (26.6) | 30 (21.4) | 45 (28.0) | 53 (22.6) | ||||
| Black | 47 (25.8) | 22 (10.3) | 39 (20.7) | 30 (14.4) | 43 (16.8) | 26 (18.6) | 43 (26.7) | 26 (11.1) | ||||
| Asian | 5 (2.7) | 4 (1.9) | 5 (2.7) | 4 (1.9) | 7 (2.7) | 2 (1.4) | 4 (2.5) | 5 (2.1) | ||||
| Indigenous | 3 (1.6) | 5 (2.3) | 6 (3.2) | 2 (1.0) | 5 (2.0) | 3 (2.1) | 5 (3.1) | 3 (1.3) | ||||
| Education (%) | ||||||||||||
| Less than high school | 59 (32.1) | 55 (25.0) | 0.009 | 61 (32.3) | 53 (24.7) | 0.062 | 67 (25.5) | 47 (33.3) | 0.229 | 55 (33.7) | 59 (24.5) | < 0.0001 |
| High school and some college/university | 51 (27.7) | 43 (19.5) | 48 (25.4) | 46 (21.4) | 65 (24.7) | 29 (20.6) | 57 (35.0) | 37 (15.4) | ||||
| Completed college/university or more | 74 (40.2) | 122 (55.5) | 80 (42.3) | 116 (54.0) | 131 (49.8) | 65 (46.1) | 51 (31.3) | 145 (60.2) | ||||
| Income (%) | ||||||||||||
| ≤ USD 1,245 | 66 (36.3) | 55 (25.0) | < 0.0001 | 64 (34.0) | 57 (26.6) | 0.008 | 78 (29.9) | 43 (30.5) | 0.705 | 71 (43.8) | 50 (20.8) | < 0.0001 |
| USD 1,246 to 3,319 | 68 (37.4) | 59 (26.8) | 67 (35.6) | 60 (28.0) | 86 (33.0) | 41 (29.1) | 59 (36.4) | 68 (28.3) | ||||
| ≥ USD 3,320 | 48 (26.4) | 106 (48.2) | 57 (30.3) | 97 (45.3) | 97 (37.2) | 57 (40.4) | 32 (19.8) | 122 (50.8) | ||||
| Private health insurance (%) | 114 (62.0) | 157 (71.4) | 0.045 | 128 (67.7) | 143 (66.5) | 0.796 | 189 (71.9) | 82 (58.2) | 0.005 | 92 (56.4) | 179 (74.3) | < 0.0001 |
| Medication adherence (%) | ||||||||||||
| Adherent | 49 (32.7) | 114 (52.3) | 0.0002 | 57 (37.0) | 106 (49.5) | 0.017 | 95 (41.9) | 68 (48.2) | 0.231 | 35 (27.1) | 128 (53.6) | < 0.0001 |
| Non-adherent | 101 (67.3) | 104 (47.7) | 97 (63.0) | 108 (50.5) | 132 (58.1) | 73 (51.8) | 94 (72.9) | 111 (46.4) | ||||
ASA = acetylsalicylic acid; ACEI = angiotensin-converting enzyme inhibitor; SD = standard deviation; USD = United States dollars.